CD8A and neoplasm: The administering of a prime-boost of aDEC205-OVA/VSV-OVA also resulted in the generation of greater SIINFEKL-specific CD8+ T cells and improved survival of tumor-bearing mice (Figures S6B, S6D, and S6E).